Nasdaq · Healthcare
IRADIMED CORP (IRMD)
As-reported financials and recent SEC filings for IRADIMED CORP, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$83.8M
Net income
$22.5M
Net margin
26.8%
Diluted EPS
$1.75
ROE
23.8%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $83.8M | $73.2M | $65.6M | $53.3M | $41.8M |
| Gross profit | $64.3M | $56.4M | $50.2M | $41.3M | $32.0M |
| Operating income | $26.1M | $22.0M | $20.0M | $15.6M | $9.8M |
| Net income | $22.5M | $19.2M | $17.2M | $12.8M | $9.3M |
| Diluted EPS | $1.75 | $1.50 | $1.35 | $1.02 | $0.74 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-24
View on EDGAR →42026-06-23
View on EDGAR →42026-06-04
View on EDGAR →1442026-06-04
View on EDGAR →42026-06-02
View on EDGAR →42026-05-28
View on EDGAR →42026-05-20
View on EDGAR →SCHEDULE 13G/A2026-05-14
View on EDGAR →Largest Healthcare peers
Go deeper on IRMD
Search IRADIMED CORP’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.